Why did NTHI spike today?

The stock price of NTHI has experienced a significant increase on July 2. According to the information I found, the company's recent appointment of a new Chief Clinical Officer and the completion of a $10.02 million shares sale by existing shareholders could have influenced the stock price surge on July 2. |code|Ticker|Name|Date|Percentage Change|market_code| |---|---|---|---|---|---| |NTHI|NTHI.O|Neonc|20250702|57.91044776119403|185| |code|Ticker|Name|Date|Post-Market Percentage Change|market_code| |---|---|---|---|---|---| |NTHI|NTHI.O|Neonc|20250702|-3.213610586011341|185| 1. **Appointment of a New Chief Clinical Officer**: NeOnc Technologies Holdings, Inc. appointed Dr. Josh Neman as its new Chief Clinical Officer (CCO). Dr. Neman's experience in cancer neuroscience and translational research could potentially enhance the company's clinical strategy and translate into positive expectations for the company's future developments. 2. **Completion of a Shares Sale**: NeOnc Technologies Holdings, Inc. filed to offer 10.02 million shares of its common stock, which could be seen as a strategic move to sell these shares on behalf of existing shareholders. This could potentially dilute the existing shares and lead to concerns about the company's financial health, which could contrarily impact the stock price. However, the context of the sale and the motivations behind it are key factors that could influence investor perceptions. In conclusion, the spike in NTHI's stock price today can be attributed to a combination of factors including the appointment of a new Chief Clinical Officer and the completion of a shares sale. These events could have led to increased investor confidence and a positive perception of the company's future prospects.